Exact Sciences Corp. (NASDAQ:EXAS) is one of 15 stocks with the biggest hedge fund momentum, after gaining 31 hedge fund holders during the fourth quarter of 2025. On February 20, the company announced that its shareholders had approved the proposed merger with Abbott Laboratories. The decision was made at a special meeting held that day. Under the terms of the merger agreement, Abbott Laboratories will acquire Exact Sciences for $105 per share in cash, a transaction valued at approximately $21 billion in ...

Core Viewpoint - Exact Sciences held a special stockholder meeting to vote on a merger agreement with Abbott Laboratories, indicating a significant corporate development that could impact its future operations and market position [2][6]. Group 1: Meeting Details - The meeting took place on February 20, 2026, and was presided over by Kevin Conroy, chairman of the board [2]. - James Herriott served as the secretary of the meeting, and a quorum was confirmed with a majority of shares present [3][7]. - The notice of the meeting was mailed to stockholders on or about January 9, 2026, in compliance with Delaware law [6]. Group 2: Proposals Voted On - Stockholders voted on three key proposals: 1. Adoption of the merger agreement with Abbott Laboratories and Badger Merger Sub I Inc., with the board recommending a vote "for" [7]. 2. An advisory, non-binding vote on executive compensation related to the merger, also recommended "for" by the board [8]. 3. Approval of an adjournment of the meeting if necessary to solicit additional proxies, with the board again recommending a vote "for" [8].

Medtronic beats quarterly profit estimates on robust demand for heart devices | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]A general view of the logo of Medtronic, a healthcare technology and pharmaceutical company, at their plant, in Galway, Ireland, April 11, 2025. REUTERS/Clodagh Kilcoyne/File Photo [Purchase Licensing Rights, opens new tab]- Companies[Medtronic Inc]Follow[Abbott Laboratories]Follow[Dexcom Inc]FollowShow more ...

Company Performance - Abbott Laboratories (NYSE:ABT) stock fell over 7% after reporting fourth-quarter 2025 sales of $11.46 billion, slightly missing the consensus estimate of $11.80 billion, with a sales increase of 4.4% on a reported basis and 3% on an organic basis [2][3] - The company reported adjusted earnings of $1.50, which was in line with Wall Street estimates [3] Market Movements - 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) shares surged 158% to $5.15 following a partnership announcement with Runway Health [9] - Eagle Bancorp, Inc. (NASDAQ:EGBN) shares increased by 18% to $28.25 after reporting better-than-expected fourth-quarter financial results [9] - Creative Media & Community Trust Corporation (NASDAQ:CMCT) shares rose 52% to $4.4494 after closing the sale of its lending division [9] - C3is Inc. (NASDAQ:CISS) shares dropped 37% to $0.088 after announcing a 1-for-20 reverse stock split [9] - Mingteng International Corporation Inc. (NASDAQ:MTEN) shares fell 34% to $0.020 following a 1-for-200 reverse stock split [9] - POET Technologies Inc. (NASDAQ:POET) shares decreased by 12% to $7.35 after announcing a $150 million offering of 20.690 million shares [9]

Core Viewpoint - Current market conditions raise concerns for retirees about the safety of stock investments, with high valuations and questionable economic conditions making it difficult to find quality investments [1] Group 1: AbbVie - AbbVie, a drugmaker that spun off from Abbott Laboratories in 2013, has consistently paid and grown its dividend, qualifying as a Dividend King with over 50 consecutive years of annual payout increases [4] - The company increased its quarterly dividend from $1.30 in early 2021 to $1.73 today, representing a 33% increase over five years, resulting in a current yield of 3.2% [5] - Despite a high payout ratio exceeding 100% due to earnings volatility from acquisitions, AbbVie has generated nearly $20 billion in free cash flow over the past 12 months, significantly surpassing the $11.5 billion paid in dividends [6] - AbbVie has a diverse product mix and has expanded its pipeline through acquisitions, positioning itself for future growth, with a low beta value of 0.35 indicating stability [7] - AbbVie is considered a solid income investment for both short-term and long-term holding [8] Group 2: Coca-Cola - Coca-Cola, alongside AbbVie, is recognized as a blue-chip stock with strong financials, demonstrating resilience by increasing in value during the market downturn in 2022 [9] - Both companies are classified as Dividend Kings, showcasing excellent track records for raising their dividends [9]

Financial Data and Key Metrics Changes - Revenue for the third quarter of fiscal 2026 increased by 23% year over year, driven by a 16% increase in product sales and a 335% increase in contract R&D revenue [3][4] - Gross margin decreased to 79% from 84% in the prior year quarter due to a less profitable product mix and increased distributor sales [4] - Net income increased by 11% to $3.38 million or $0.70 per diluted share, up from $3.05 million or $0.63 per share [6][7] - Total operating expenses decreased by 12% compared to the third quarter of fiscal 2025 [4] Business Line Data and Key Metrics Changes - Product sales increased by 16%, while contract R&D revenue saw a significant increase of 335% [4] - The decrease in R&D expenses was attributed to the completion of certain projects and resource reallocation [5] Market Data and Key Metrics Changes - For the first nine months of fiscal 2026, total revenue increased by 0.4% to $18.7 million, with a 0.8% increase in product sales offset by an 8% decrease in contract R&D [8] - Accounts receivable decreased by $1.1 million, indicating improved customer payment timing [8] Company Strategy and Development Direction - The company aims to develop advanced electronics for high-value markets, including medical devices and autonomous vehicles, focusing on miniaturization and high sensitivity [12] - New equipment has been installed to enhance production capabilities, allowing for more precise manufacturing of spintronic devices [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to a more normal flow in the defense business, which had been relatively weak [35] - The company is focused on increasing sales to existing customers while also adding new products to their portfolio [40] Other Important Information - The effective tax rate increased to 20% due to non-cash impacts of tax law changes, with an expected full-year tax rate of 16%-17% [6] - The company has made significant investments in marketing and trade shows, which are expected to yield positive results in future sales [27][28] Q&A Session Summary Question: Discussion on magnetic navigation in GPS-compromised areas - Management acknowledged the potential of their sensors for this application but noted that the technology is still evolving and not yet mature [18][19] Question: Status of new equipment and its impact on sales - Management confirmed that the new equipment is on schedule and is expected to enhance product sales and profitability [20][21] Question: Inventory levels of distributors - Management indicated that distributor sales are picking up, suggesting that previous inventory issues have been resolved [23] Question: Comparison of intellectual property with competitors - Management stated that while they operate in a different market than Everspin, they believe their intellectual property has significant value and are open to licensing opportunities [24] Question: Potential for recurring customer orders - Management emphasized the importance of existing customers and the goal to increase sales through new products and repeat orders [40]

Market Overview - The Australian share market finished up on Friday, with the ASX 200 increasing by 0.5%, or 42.90 points, to 8903.90, marking a weekly gain of 1.6% after five consecutive days of increases, the longest winning streak since May 2025 [1] Technology Sector - Technology stocks performed strongly, driven by Taiwan Semiconductor Manufacturing's forecast of nearly 30% revenue growth in 2026, which exceeded analyst expectations and alleviated concerns regarding AI-related demand. Local tech stocks such as NextDC rose by 3.5% to $13 and Life360 by 1.7% to $29.23 [2] Banking Sector - Major banks contributed to the market rally, with Commonwealth Bank shares rising 0.5% to $154.30 and ANZ shares also up 0.5% to $37.52. National Australia Bank shares increased by 0.7% to $42.67, Westpac shares rose 1.8% to $39.19, and Macquarie shares were up 2.6% to $211.86 [3][2] Mining Sector - Shares in major miners experienced profit-taking after strong gains, with BHP shares falling 0.8% to $48.99 after a weekly rise of over 6%. This decline was influenced by a drop in oil prices following comments from US President Donald Trump regarding Iran [4] Energy Sector - Energy stocks also saw declines, with Woodside shares down 1.4% to $23.68 and Santos shares falling 1.6% to $6.23, reflecting the broader market reaction to falling oil prices [5] Company-Specific News - Capstone Copper shares surged 7.1% to $15.63 after meeting its annual copper guidance of 224,764 tonnes, a company record. Catalyst Metals shares climbed 14.7% to $9 following record quarterly production at Plutonic and positive broker reviews [6] - Conversely, Novonix shares dropped 15.8% to 42.5¢ after delaying the start of mass production of anode material for Panasonic Energy to the second half of 2027 [7] Upcoming Economic Data - The December labour force survey is expected to show an increase of about 35,000 jobs, maintaining the unemployment rate at 4.3% despite a projected rise in the participation rate [8] - In the US, the core personal consumption expenditures (PCE) price index is anticipated to rise by 2.8% year-over-year [9] - China is set to release various economic indicators, with the fourth-quarter GDP growth expected to be around 4.9%, aligning with the government's target of approximately 5% growth [10] - Australia will also see quarterly updates from several mining and energy companies, including BHP and Santos, while Wall Street will report fourth-quarter earnings from major firms like Netflix and Johnson & Johnson [11]

Core Viewpoint - Boston Scientific Corporation is a prominent player in the medical device industry, focusing on innovative solutions across various healthcare segments, particularly in interventional specialties like cardiology, urology, and neurology [1] Group 1: Company Developments - On January 14, 2026, Citigroup upgraded Boston Scientific's rating to "Buy," with the stock priced at $94.14, reflecting confidence in the company's strategic moves to enhance its market position [2] - The company announced a definitive agreement to acquire Valencia Technologies Corporation, which specializes in innovative solutions for bladder dysfunction, aiming to strengthen its urology offerings [4] Group 2: Financial Performance - Boston Scientific is experiencing an expansion in profit margins, driven by growth in its electrophysiology and WATCHMAN franchises, which is improving earnings quality and supporting growth in the MedTech sector [3] - The stock price of Boston Scientific is currently $94.14, with a market capitalization of approximately $139.6 billion, and a trading volume of 9,689,369 shares [5]

Core Viewpoint - Dexcom, Inc. is a key player in the medical technology sector, focusing on continuous glucose monitoring systems for diabetes management, with a recent price target set by Barclays indicating a slight potential upside for investors [1][5]. Financial Performance - Dexcom announced preliminary, unaudited financial results for Q4 and fiscal year 2025, along with an initial outlook for 2026 [2][5]. - The stock price is currently at $68.96, reflecting a 2.31% increase or $1.56 from previous trading [2]. Stock Performance - Over the past year, Dexcom's stock has seen significant fluctuations, with a high of $93.25 and a low of $54.11, indicating volatility in the market [3][5]. - The company maintains a market capitalization of approximately $26.98 billion, suggesting strong investor confidence in its growth potential [3]. Market Activity - Today's trading volume for Dexcom is 1,976,722 shares, indicating active investor interest in the stock [4]. - Barclays' price target of $71 reflects market anticipation of Dexcom's future growth, supported by its recent financial announcements [4][5].

Core Viewpoint - SAB Biotherapeutics, Inc. has appointed David Zaccardelli, Pharm.D. as Chair of the Board and Rita Jain, M.D. as an independent director, which is expected to enhance the company's strategic direction and growth potential in developing therapies for autoimmune diseases, particularly Type 1 Diabetes (T1D) [2][4][5]. Group 1: Appointments and Expertise - David Zaccardelli brings over 20 years of biopharmaceutical experience, having successfully led companies from clinical stages to commercialization, including the launch of Ohtuvayre, a notable biotech product [4][8]. - Rita Jain has more than two decades of leadership experience in biopharmaceutical development, particularly in autoimmune and inflammatory diseases, and has held key positions in various companies [6][9]. Group 2: Company Focus and Product Development - SAB Biotherapeutics is focused on developing a fully human anti-thymocyte immunoglobulin (hATG) for T1D and other autoimmune diseases, with its lead candidate, SAB-142, aiming to modify the disease progression in T1D patients [2][10]. - The company utilizes advanced genetic engineering and proprietary technology to produce high-potency human immunoglobulin G (hIgG) without the need for human donors, which positions it to address significant unmet medical needs [10].